CMND — Clearmind Medicine Income Statement
0.000.00%
Last trade - 00:00
- CA$5.96m
- -CA$1.47m
2019 October 31st | 2020 October 31st | R2021 October 31st | R2022 October 31st | 2023 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.079 | 0.173 | 2.93 | 6.25 | 6.3 |
Operating Profit | -0.079 | -0.173 | -2.93 | -6.25 | -6.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.079 | -0.173 | -2.96 | -6.87 | -8.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.079 | -0.173 | -2.96 | -6.89 | -8.62 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.079 | -0.173 | -2.96 | -6.89 | -8.62 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.079 | -0.173 | -2.96 | -6.89 | -8.62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.43 | -9.56 | -95.4 | -159 | -42.6 |